-
Stelara Biosimilar Ustekinumab-aekn Recieves FDA Approval
19 Apr 2024 20:21 GMT
… in the treatment of immune mediated diseases.
FDA approval was … development program for the drug included data from 2 … savings, while providing additional treatment options for patients.
Alvotech … ), aflibercept (Eylea), and denosumab (Prolia/Xgeva).2
READ …
-
Athira Pharma Welcomes Dr. Javier San Martin as Chief Medical Officer
15 Apr 2024 14:03 GMT
… “Javier’s decades of drug development experience will be … the first-in-human trial of ATH-1105 in … Arrowhead Pharmaceuticals, where he served as Chief Medical Officer … of Prolia (denosumab) for the treatment of postmenopausal osteoporosis. Prior to Amgen, …
-
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
15 Apr 2024 11:00 GMT
… as a pioneer in drug development for patients with … the first-in-human trial of ATH-1105 in … from Arrowhead Pharmaceuticals, where he served as Chief Medical Officer … of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis. Prior to Amgen, Dr …
-
Looking At Amgen's Recent Unusual Options Activity
12 Apr 2024 17:33 GMT
… About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include … 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) … several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has …
-
11 Best Biotech ETFs To Buy
09 Apr 2024 11:45 GMT
… :GEHC) to enhance medical imaging. Raj Joshi, … , focusing on biotechnology and pharmaceutical companies. It … drug Repatha, bone‐strengthening drug Prolia and cancer drug Blincyto … – Biotech Therapeutics, focused on therapeutic treatments, and Biotech Tools …
-
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
08 Apr 2024 10:07 GMT
… clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar … such as for the treatment of osteoporosis in … , and innovative biologic medicines for patients worldwide with … ; the impact of pharmaceutical industry regulation and health …
-
Amgen Unusual Options Activity For April 02
02 Apr 2024 18:40 GMT
… About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include … 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) … several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has …
-
Amgen's Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says
28 Mar 2024 19:16 GMT
… early-stage human trials of its experimental obesity drug AMG 133 (maridebart … .
Also Read: Amgen’s Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning.
The … based on the CodeBreaK 200 trial results for adults with previously …
-
Amgen Options Trading: A Deep Dive into Market Sentiment
28 Mar 2024 17:16 GMT
… About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include … 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) … several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has …
-
CMS Estimates Savings for Patients from Medicare Inflation Rebates
26 Mar 2024 21:13 GMT
… certain drugs. The Centers for Medicare & Medicaid Services … Minocin (minocycline): infections; Torrent Pharmaceuticals
Nexterone (amiodarone) (Baxter): … : Recordati Rare Diseases
Prolia (denosumab): osteoporosis; Amgen
Romidepsin (non-lyophilized) …
About
© 1995-2024